Cara Therapeutics Inc (NASDAQ:CARA) shared data from a sub-study of the KARE Phase 2 trial of Korsuva (difelikefalin) improved itch and inflammatory biomarkers in atopic dermatitis (AD) patients with moderate-to-severe pruritus.
- The biomarker data were presented during the Late-Breaking Research: Clinical Trials session at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
- The sub-study, which included 40 patients from the KARE trial, characterized the effect of oral Korsuva on pruritus- and AD-related gene expression using baseline and week 12 skin biopsies.
- Data pooled indicated that treatment with oral Korsuva altered the expression of multiple individual pruritus- and AD-related genes.
- Gene set variation analysis confirmed downregulation of pruritus-related genes and the Th2 pathway following 12 weeks of treatment with oral Korsuva, but not placebo.
- Price Action: CARA shares are trading at $12.34 during the market session on the last check Monday.
